ELAVL1 and cancer: Furthermore, MS-444, as well as other inhibitors, like DHTS and CMLD-2, were only tested against specific types of cancer (including colorectal cancer, adenocarcinoma, and glioma), while their effect on other HuR-associated pathological conditions, like inflammation or neurological disorders, is currently unknown [49].